2026-01-14 - Analysis Report
**Company Overview:**
Merck & Co Inc, a leading healthcare company.

**Return Rate Comparison:**

* Cumulative Return (MRK) = 25.01%
* Cumulative Return (VOO) = 93.94%

* Degree of Divergence: -68.93% (Difference in Cumulative Return)

**Alpha, Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 24.0% | 14.7% | 21.0% | 0.7 | 182.1B |
| 2017-2019 | 37.0% | 14.7% | 20.0% | 0.7 | 216.8B |
| 2018-2020 | 13.0% | 19.3% | -8.0% | 0.7 | 195.0B |
| 2019-2021 | 0.0% | 19.3% | -43.0% | 0.6 | 191.4B |
| 2020-2022 | 14.0% | 16.3% | 16.0% | 0.5 | 277.1B |
| 2021-2023 | 31.0% | 14.3% | 30.0% | 0.3 | 272.3B |
| 2022-2024 | -5.0% | 24.9% | -24.0% | 0.3 | 248.5B |
| 2023-2025 | -24.0% | 39.0% | -86.0% | 0.3 | 262.9B |

**Recent Stock Price Fluctuations:**

* Close = $108.26 
* Last-Market = $108.26 (previous close = $109.19)
* 5-day SMA = $109.51
* 20-day SMA = $105.54
* 60-day SMA = $97.24

**R/S/D Analysis and Indicators:**

* Market Risk Indicator (MRI) = 0.70 (Medium Investment)
* RSI = 64.07
* PPO = -0.05
* Expected Return (%) = -26.70%
* Recent (20 days) relative divergence change = 1.40 (improving)
* 7-day Rank change = -3 (rank down)
* 7-day Dynamic Expected Return change = 0.60 (improving)

**Recent News & Significant Events:**

* [2025-12-30] FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential - Yahoo Finance (news.google.com)
* [2025-12-24] Is Merck Stock’s Run Legitimate? - Forbes (news.google.com)
* [2026-01-13] Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda - TechStock²
* [2026-01-13] Merck (MRK) Stock; Declines 1.2% as $70B Mid-2030s Target Fails to Excite Investors - CoinCentral
* [2026-01-13] Merck & Co., Inc. $MRK Shares Sold by S Bank Fund Management Ltd - MarketBeat
* [2026-01-09] What Is Happening With Merck Stock? - Trefis

* FDA fast-tracking two new drugs, lifting mid-2030s target.

**Analyst Opinions:**

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
	+ Opinions: 27
	+ Target Price (avg/high/low): 113.33 / 135.00 / 83.00

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
|-----|-----|----------|
| 2025-11-05 | 2.32 | $17.28B |
| 2025-08-05 | 1.76 | $15.81B |
| 2025-05-02 | 2.01 | $15.53B |
| 2024-11-06 | 1.25 | $16.66B |
| 2025-11-05 | 1.25 | $16.66B |

* Quarterly EPS and Revenue growth is volatile.
* Recent quarterly earnings growth is -3.33% YoY.

**Financial Information:**

Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

* Profit margin is consistently around 75-78%.
* Revenue growth slows down.

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

* Equity is consistently increasing.
* ROE is below industry average.

**Comprehensive Analysis (Summary of previous items):**
Merck stock's return rate is significantly lower than the S&P 500 (VOO). Recent volatility and downward movement of stock price is a concern. Market risk indicator is medium-high, indicating potential for further price movement. Analyst consensus is buy. Recent earnings analysis shows volatility and slowdown in revenue growth. Financial information shows consistent profit margin and equity growth, but ROE is below industry average.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.